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Introduction: Two-thirds of patients in the United States
with newly diagnosed lung cancer would not meet the
current U.S. Preventive Services Task Force (USPSTF)
screening criteria, which suggests a need for amendment of
the deﬁnition of high risk. To provide evidence of additional
high-risk subpopulations and estimated gains and losses
from using different criteria for screening eligibility, we
conducted a two-step study using three cohorts.
Methods: The two prospective cohorts comprised 5988
patients in whom primary lung cancer was diagnosed be-
tween 1997 and 2011 (the hospital cohort) and 850
deﬁned-community residents (the community cohort); the
retrospective cohort consisted of the population of Olmsted
County, Minnesota, which was observed for 28 years
(1984–2011). Subgroups of patients with lung cancer who
might have been identiﬁed using additional determinates
were estimated and compared between the community and
hospital cohorts. The ﬁndings were supported by indirect
comparative projections of two ratios: beneﬁt to harm and
cost to effectiveness.
Results: Former cigarette smokers who had a smoking
history of 30 or more pack-years and 15 to 30 quit-years
and were 55 to 80 years old formed the largest subgroup
not meeting the current screening criteria; they constituted
12% of the hospital cohort and 17% of community cohort.
Using the expanded criteria suggested by our study may
add 19% more CT examinations for detecting 16% more
cases when compared with the USPSTF criteria. Meanwhile,
the increases in false-positive results, overdiagnosis, and
radiation-related lung cancer deaths are 0.6%, 0.1%, and
4.0%, respectively.Journal of Thoracic Oncology Vol. 11 No. 2: 194-202Conclusions: Current USPSTF screening criteria exclude
many patients who are at high risk for development of lung
cancer. Including individuals who are younger than 81
years, have a smoking history of 30 or more pack-years, and
have quit for 15 to 30 years may signiﬁcantly increase the
number of cases of non-overdiagnosed screen-detected lung
cancer, does not signiﬁcantly add to the number of false-
positive cases, and saves more lives with an acceptable
amount of elevated exposure to radiation and cost.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: Lung cancer; Low-dose CT; Screening; Smoking
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Introduction
With the declining percentage of the U.S. population
that smokes, the incidence of lung cancer and mortality
due to lung cancer have been decreasing among men for
February 2016 Subpopulations at High Risk for Lung Cancer 195the past three decades and, only recently, have begun
showing a decrease among women.1 Meanwhile, former
cigarette smokers remain at high risk for lung cancer,
albeit at lower risk than had they continued smoking.2
As a consequence, more cases of lung cancer are now
being diagnosed in former smokers rather than in cur-
rent smokers.3 Speciﬁcally, less than 18% of U.S. adults
are current smokers and more than 30% are former
smokers.3,4 As of 2014, use of low-dose computed to-
mography (LDCT) screening for lung cancer was rec-
ommended by the U.S. Preventive Services Task Force
(USPSTF) for annual screening of people aged 55 to 80
years who have a history of smoking cigarettes at a rate
of 30 or more pack-years and either are current smokers
or have quit within the past 15 years.5,6 This recom-
mendation was based on the entry criteria of the Na-
tional Lung Screening Trial (NLST) but with an extension
of the upper age limit of 74.7 However, our recent report
showed that approximately two-thirds of patients with
newly diagnosed lung cancer would not have met the
current USPSTF criteria for being at high risk for
development of lung cancer and thus eligible for LDCT
screening.8 In particular, we found a 24% falloff in
meeting the eligibility criteria for screening (from 57%
in 1984–1990 to 43% in 2005–2011), which exceeded
the 17% decline in incidence of lung cancer (from 53 to
44 cases per 100,000 population) within the same time
intervals. Herein we report our further investigations to
delineate the high-risk subpopulations on the basis of
evidence from two prospective cohorts of patients with
lung cancer and a retrospective community cohort. Our
goal was to improve the identiﬁcation of individuals at
high risk for development of lung cancer by (1)
demonstrating the chronological patterns of patients
who would have been the beneﬁciaries or “missed-outs”
under the USPSTF criteria for lung cancer screening in
two contrasting cohorts and (2) providing indirect evi-
dence of a new subpopulation that should be included in
the deﬁnition of high risk and the potential beneﬁt
versus harm and projected cost versus effectiveness of
including them.Methods
Study Population
This study included two steps: description and vali-
dation. Step 1 used two prospectively observed cohorts of
individuals with lung cancer, one based on patients
referred toMayo Clinic (i.e., the hospital cohort, n¼ 5988)
and the other consisting of residents of Olmsted County,
Minnesota (i.e., the community cohort, n ¼ 850). The
hospital cohort included patients who had pathologically
conﬁrmed primary lung cancer diagnosed at Mayo Clinic
in Minnesota during a 15-year period (between January 1,1997 and December 31, 2011)9 and were not Olmsted
County residents. The community cohort was matched to
the same 15-year period of diagnosis as the hospital
cohort.8 All cases were identiﬁed using the Rochester
Epidemiology Project database, which has for more than
60 years maintained a comprehensive system linking the
medical records of almost all persons residing in Olmsted
County.10,11 This population comprises approximately
140,000 persons, 83% of whom are non-Hispanic whites;
it is socioeconomically similar to the white population of
the United States and is representative of the population
of the midwestern United States. More details were pub-
lished previously.8,12 This study was approved by the
institutional review boards of Mayo Clinic and Olmsted
County Medical Center.
The objective of step 2 was to provide indirect evi-
dence supporting the ﬁndings in step 1. We have derived
comparative beneﬁt-to-harm and cost-to-effectiveness
ratios for three sets of criteriadNLST, USPSTF, and the
expanded criteria suggested by our study on the basis of
the information provided in the models by de Koning
et al.6 Although hypothetical and indirect, the compre-
hensive models built by de Koning et al. are very helpful
in initial evaluation of the impact (positive and negative)
of a potential high-risk subpopulation given the lack of
individual-level smoking history data or up-to-date and
accurate smoking history information for entire pop-
ulations of interest. Brieﬂy, the modeling groups stan-
dardized input data on smoking histories and non–lung
cancer mortality to simulate life histories of the U.S.
cohort born in 1950, which uses an updated version of
the National Cancer Institute’s smoking history gener-
ator. Their models assumed 100% adherence to
screening criteria; the data derived from trials of short
duration (e.g., 4 to 9 years) were extrapolated to lifetime
follow-up, and smoking history data from one to two
decades ago were assumed to be current.6,13–16
Speciﬁcally, we have adapted and integrated the
following 11 items selected from Tables 1 and 2 in the
article by de Konig et al.6: (1) total number of CT ex-
aminations, including screening examinations; (2) num-
ber of screening-detected cases; (3) reduction in lung
cancer mortality; (4) total cases detected at an early
stage; (5) average number of screening examinations per
person screened; (6) screening examinations per averted
death from lung cancer; (7) screening examinations per
life year gained; (8) average number of false-positive
results per person screened; (9) number of instances
of overdiagnosis; (10) overdiagnosis as a percentage of
screening-detected cases; and (11) radiation-related
lung cancer deaths.
Their comprehensive models standardized input data
on smoking histories and non-lung cancer mortality to
simulate life histories of the U.S. 1950 birth cohort.15–18
Table 1. Demographic and Clinical Features of the Community and Hospital Cohorts of Individuals with Lung Cancer
Diagnosed in 1997–2011
Characteristics
Prospectively Enrolled and Monitored Lung Cancer Patients
(N ¼ 6838)
p ValueCommunity Cohort (n ¼ 850) Hospital Cohort (n ¼ 5988)
Age at diagnosis, year <0.0001
Mean ± SD 68.8 ± 11.0 65.0 ± 11.1
Median (Q1, Q3) 70.0 (62.0, 77.0) 66.0 (58.0, 73.0)
Sex 0.2602
Male, n (%) 444 (52.2%) 3251 (54.3%)
Mean age ± SD 68.9 ± 10.6 66.4 ± 10.9
Median age (Q1, Q3) 70.0 (63.0, 77.0) 68.0 (60.0, 74.0)
Female, n (%) 406 (47.8%) 2737 (45.7%)
Mean age ± SD 68.7 ± 11.4 63.4 ± 11.2
Median age (Q1, Q3) 70.0 (61.0, 77.0) 65.0 (56.0, 71.0)
Race, n (%)a 0.0335
White 811 (95.4%) 5577 (93.5%)
Other 39 (4.6%) 386 (6.5%)
Cigarette smoking status, n (%) <0.0001
Never smoker 77 (9.0%) 1008 (16.8%)
Former smoker 422 (49.8%) 3056 (51.0%)
Current smoker 350 (41.2%) 1924 (32.1%)
Smoking pack-years (for smokers), n (%)a 0.0025
1–19 88 (11.4%) 781 (15.8%)
20–29 82 (10.6%) 583 (11.8%)
30 601 (78.0%) 3580 (72.4%)
Quit-years (for former smokers), n (%) 0.0001
<15 years 241 (57.1%) 1443 (47.2%)
15 years 181 (42.9%) 1613 (52.8%)
aData missing on the race of 13 patients (0.2%) in the hospital cohort and on pack-years of smoking by one patient (0.1%) in the community
cohort and 27 patients (0.5%) in the hospital cohort, respectively.
SD, standard deviation; Q, quarter.
196 Yang et al Journal of Thoracic Oncology Vol. 11 No. 2We used an A-55-80-30-25 screening program as in the
models of de Koning et al., in which A stands for annual
LDCT, 55 is the start age, 80 is the stop age, 30 indicates
a smoking history of 30 or more pack-years, and 25 in-
dicates 25 or fewer years since quitting; this model is
most similar to our ﬁndings as supported by our previ-
ous work.2,8
Data Collection
For each patient, medical records were reviewed and
abstracted for the following information: demographic
characteristics (age, sex, and race), history of occupa-
tional exposure, history of tobacco exposure, histologic
diagnosis of lung cancer, staging, treatment modality,
family history of lung cancer, and other comorbid con-
ditions. For the hospital cohort, information was also
obtained from an interview, follow-up questionnaire, or
both. The patient interview and/or annual follow-up
questionnaire obtained detailed information on history
of tobacco exposure, history of occupational exposure,
and family history of cancer. The information on history
of tobacco exposure included current or past use,duration, average number of cigarettes smoked per day,
and number of years since quitting smoking. Current
smokers were deﬁned as those who were actively
smoking, as well as those who had stopped smoking
within 1 year before being receiving a diagnosis of lung
cancer. Former smokers were deﬁned as those who had
quit smoking for at least 1 year before receiving their
diagnosis. Never-smokers were deﬁned as those who
had smoked fewer than 100 cigarettes during their
lifetime. Pack-years are calculated by multiplying the
number of packs smoked daily by the number of years
smoked. History of chronic obstructive pulmonary dis-
ease (COPD) was determined on the basis of an explicit
diagnosis documented in the medical history with pul-
monary function tests in the medical record. Family
history of lung cancer was deﬁned as having at least one
ﬁrst-degree relative (parent, sibling, or offspring) with
lung cancer. Positive exposure to asbestos was based on
self-reported direct contact with the asbestos-containing
material for at least 1 year and corroborated by occu-
pational history (job titles and tasks) at least 5 years
before the diagnosis of lung cancer.
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In step 1, we performed three descriptive analyses:
(1) calculation and sorting of the frequencies of selected
key characteristics, including age groups (50–54, 55–80,
>80 years), smoking status (ever-smokers versus never-
smokers), smoking history in terms of pack-years (<20,
20–30, >30) and years since quitting smoking (quit-
years; <15, 15–30, >30), history of COPD and/or lung
cancer, history of asbestos exposure, and family history
of lung cancer in ﬁrst-degree relatives; (2) illustration by
pie charts of subgroups of those not meeting the USPSTF
criteria; and (3) calculation and illustration of the dis-
tribution of pack-years and quit-years in patients not
meeting the USPSTF criteria.
In step 2, we performed three levels of hypothetical
comparisons: (1) the relative gain achieved by using the
USPSTF criteria versus the NLST criteria, (2) the relative
gain achieved by using the criteria from our study versus
those of the NLST, and (3) the relative gain achieved by
using the criteria from our study versus those of the
USPSTF. For clarity and simplicity in the comparisons,
we set the estimates of the NLST as the standardized
reference values at 100 or 100% when involving the
actual numbers (e.g., total numbers of CT examinations
and screening-detected cases). For parameters of com-
mon knowledge (e.g., reduction in lung cancer mortality
and total cases detected at an early stage), the original
model-based percentage for the NLST was used as the
comparator, with the predicted change (%) resulting
from using the USPSTF criteria and our study criteria.
For the estimated means (e.g., average screening exam-
inations per person screened per life year gained,
average false-positive results per person screened, and
over diagnosis of screening-detected cases), the original
model-based average for the NLST was used as the
comparator, with the predicted change (%) resulting
from using the USPSTF criteria and our study criteria.Results
Characteristics of Patients in the Two
Prospective Lung Cancer Cohorts
Table 1 presents basic information and comparisons of
5988 hospital and 850 community lung cancer cohort
members in whom lung cancer was diagnosed between
1997 and 2011. Patients’ characteristics differed between
the two cohorts, reﬂecting the typical referral bias in a
tertiary medical center. All variables except sex ratio were
signiﬁcantly different; speciﬁcally, compared with the
community cohort, the hospital cohort was younger and
characterized by a higher representation of never-
smokers, lighter smokers, and long-term quitters. Despite
these differences, the two cohorts showed remarkably
consistent results in the following three respects:
198 Yang et al Journal of Thoracic Oncology Vol. 11 No. 2Subgroups Outside the USPSTF Screening Criteria.
Figure 1 illustrates the relative proportions of screening-
eligible and screening-ineligible patients in the two pa-
tient cohorts in order of subgroup frequency. Individuals
falling under more than one variable were grouped
within the larger subgroup. The frequencies of the
selected risk factors in each cohort are summarized in
Table 1. When the community cohort was used as a
standard reference group (Fig. 1A), 46% of cases were
found to meet the USPSTF criteria, whereas only 38% in
the hospital cohort were found to do so. In the areas of
the pie charts other than that representing those patients
meeting the USPSTF screening criteria, we compared
eight factors characterizing the patients in terms of
additional intensity of tobacco smoking exposure, age of
50 to 54 years at the time of diagnosis of lung cancer,
family and personal history of lung cancer, and history of
COPD and asbestos exposure. The two most frequently
occurring characteristics in both cohorts were “quit
smoking for 15 to 30 years” (12% versus 17%) and
“smoking history of 20 to 30 pack-years” (6.3% versus
6.2%). In both cohorts, “history of COPD” (1.9% versus
2.2%) and “personal history of lung cancer” (0.3%
versus 0.6%) were the lowest in frequency of all pre-
sented factors.
Distribution of Pack-Years and Quit-Years in
Patients Ineligible for Screening Under the USPSTF
Criteria. We examined the distribution of pack-years
and quit-years among those in both cohorts who were
younger than 81 years and ineligible according to theFigure 1. Subgroup distribution by frequency of known risk fac
years and in whom lung cancer was diagnosed in 1997–2011: (AUSPSTF screening criteria, as depicted in Figures 2A and
2B; clearly standing out is the subgroup of those who
had a smoking history of at least 30 pack-years and had
quit smoking for more than 15 years. Therefore, we
propose that being a former smoker who has quit
smoking for 15 to 30 years and has a smoking history of
at least 30 pack-years be added to the current USPSTF
screening criteria.
Temporal Pattern Change According to the NLST and
USPSTF Screening Criteria. Of those patients in the
community cohort, 35.7% would have met the entry
criteria of the NLST and 45.8% would have met the
USPSTF screening criteria. Of those patients in the hos-
pital cohort, only 33.4% and 38.2% would have met the
respective criteria. Figures 3A and B illustrate the rela-
tive proportion of alternative criteria over three 5-year
intervals for both cohorts (i.e., 1997–2001, 2002–2006,
and 2007–2011). The bottom portion of each bar rep-
resents the NLST criteria (age 55–74 years, smoking
history of at least 30 pack-years, and former smoker
with 15 or fewer quit-years), the middle portion of each
bar represents those aged 75 to 80 years (extended ac-
cording to the USPSTF criteria), and the top portion
shows our proposed addition of former smokers with a
smoking history of at least 30 pack-years and 15 to 30
quit-years. More speciﬁcally, in the community cohort
(see Fig. 3A), the percentage of patients who were
eligible according to the NLST decreased from 40.8% to
31.9% (p ¼ 0.017) and the percentage of those eligible
according to the USPSTF decreased from 53.2% totors in patients with lung cancer who were younger than 81
) community cohort and (B) hospital cohort.
February 2016 Subpopulations at High Risk for Lung Cancer 19940.5% (p ¼ 0.002) over the 15-year period. On the other
hand, the proportion of those eligible according to the
proposed criteria increased; particularly noteworthy is
the fact that coverage of patients meeting the proposed
criteria in the most recent time interval was at 52%.
The same trends toward decreasing eligibility were
observed in the hospital cohort (see Fig. 3B): the per-
centage of those eligible according to the NLST criteria
decreased from 35.2% to 31.0% (p ¼ 0.003), and the
percentage of those eligible according to the USPSTF
criteria decreased from40.3% to 35.1% (p< 0.001). More
strikingly in the most recent time interval, the percentage
of lung cancer cases added by the subgroup with 15 to 30
quit-years (17.6%) ismore than four times higher than the
4.1% increase achieved by adding the USPSTF criterion of
“those 75 to 80 years old” to the NLST criteria.
Potential Beneﬁt versus Harm and Projected Cost versus
Effectiveness. Table 2 provides hypothetical projections
of beneﬁt versus harm and cost versus effectiveness
through 11 itemized comparisons (labeled columns 1–
11), reﬂecting meaningful relative gains and losses with
the three sets of criteriadthe NLST, USPSTF, and our
studydand purposefully not involving actual expense
and productivity measures. Five illustrative points
regarding pros and cons are listed in the following
paragraphs.
1. With regard to the balance of total numbers of
computed tomography (CT) screening examinations
and screening-detected lung cancer cases (columns 1
and 2), when the NLST estimates are set at 100 as a
reference, using the USPSTF criteria would add 8.2%
more CT examinations, for a 19.7% gain in screening-
detected cases of lung cancer, whereas the criteria
suggested by our study may add 29% more CT ex-
aminations, for a 39% gain in screening-detected lung
cancer cases. With regard to our study criteria versus
those of the USPSTF, 19% more CT examinationsFigure 2. Distribution of pack-years and quit-years in patients y
Screening Trial and U.S. Preventive Services Task Force criteriawould be the trade-off for 16% more cases of lung
cancer detected.
2. In the models in which the NLST criteria reduce lung
cancer mortality by 12.3%, a greater reduction in
mortality may be achieved by using the criteria sug-
gested by our study than by the predicted reduction
according to the USPSTF criteria (column 3, i.e., 15.8%
[12.3 þ 3.5] versus 14% [12.3 þ 1.7]). Our study
criteria versus those of the USPSTF provide a 1.8%
greater reduction in lung cancer mortality.
3. In the models in which 48.4% of the total cases
detected in the NLST were in an early stage, a higher
rate of detection of early-stage lung cancer may be
achieved with the criteria suggested by our study than
the predicted increase by the USPSTF criteria (column
4, i.e., 52.1% [48.4 þ 3.7] versus 50.5% [48.4 þ 2.1]).
Our study criteria versus those of the USPSTF result in
a 1.6% increase in detecting lung cancer at an early
stage.
4. When the average numbers of screening examinations
per person screened (column 5), per lung cancer
death averted (column 6), and per life year gained
(column 7) were weighed, the reference criteria of the
NLST yielded 13.3, 577, and 49, respectively.
Compared with the NLST criteria, the USPSTF criteria
resulted in gains of 1.1, 3, and 3, whereas use of our
study criteria resulted in gains of 3.1, 6, and 5,
respectively. Use of our study criteria versus those of
the USPSTF resulted in an increase in number of
average screening examinations by two per person
screened, three per lung cancer death averted, and
two per life year gained, respectively.
5. With regard to concerns regarding false positivity
(column 8), overdiagnosed cases (columns 9–10), and
radiation-related lung cancer deaths (column 11), the
increases in false-positive results, overdiagnosis, and
radiation-related lung cancer death are minimal by all
comparisons.ounger than 81 years who were ineligible by the National Lung
, 1997–2011: (A) community cohort and (B) hospital cohort.
Figure 3. Temporal pattern of percentage of the community cohort (A) and hospital cohort (B) covered by the National Lung
Screening Trial (NLST) and U.S. Preventive Services Task Force (USPSTF) screening criteria, 1997–2011.
200 Yang et al Journal of Thoracic Oncology Vol. 11 No. 2Discussion
According to the latest data from the Surveillance
Epidemiology and End Results Program and National
Program of Cancer Registries, the incidence of lung
cancer among men in the United States peaked in 1984
but continued to increase among women until 2006.19
We found a similar trend in the population of Olmsted
County (Fig. 4), thus supporting the validity of consid-
ering our data to be generalizable to the United States’
general population. During 2005–2012, the percentage
of heavy smokers in the United States who smoked 30
or more cigarettes per day declined signiﬁcantly, from
12.6% to 7.0%.3 Our recent report revealed that less
than 40% of subjects in whom lung cancer has
been diagnosed would meet the USPSTF screening
criteria,8 thus conﬁrming the need to expand the current
criteria if the desire is to target the population at high
risk.20,21
Since 2002, former smokers have outnumbered cur-
rent smokers, and from 1998 to 2012, the percentage of
U.S. adults who were current cigarette smokers declined
from 24.1% to 18.1%.3,4 Former smokers remain atFigure 4. Trends in the incidence of lung cancer, Olmsted Coun
adjusted by age (A) and by age (B).much higher risk for lung cancer than never-smokers
even though their risk is lower than if they had
continued to smoke.2,14–15 The fact that most lung cancer
cases diagnosed in the United States today are in former
smokers reﬂects the success of smoking cessation efforts
and also reﬂects the continued high-risk status of former
smokers.22–25 We speciﬁcally evaluated quitting smoking
for 15 to 30 years because our previous study showed
that risk for the development of lung adenocarcinoma
remained elevated for up to 30 years beyond smoking
cessation for former heavy and light smokers alike.2 We
have also reported that in Olmsted County, the trend has
been toward a decrease in the proportion of patients
with lung cancer and a smoking history of 30 or more
pack-years and an increase in lung cancer among former
smokers who had quit smoking for at least 15 years.8 A
striking observation from the current study is the dis-
tribution of pack-years and quit-years in those ineligible
for screening under the USPSTF criteria (as is shown in
Fig. 2): we found that compared with other risk cate-
gories, “quit smoking for 15 to 30 years” accounted for
the greatest percentage of those with lung cancer.ty, Minnesota, 1984–2011, by calendar year of diagnosis and
February 2016 Subpopulations at High Risk for Lung Cancer 201Our results also showed that, compared with when
the NLST entry criteria were used, the number of lung
cancer cases discovered among those in the community
and hospital cohorts who met the USPSTF criteria
increased by only 4.1% to 8.6% (see Fig. 3, 2007–2011).
In contrast, when “former smokers with 15 to 30 quit-
years” was added, the increase in those who met the
criteria and in whom lung cancer actually developed
ranged from 13.3% to 17.6%. Therefore, assuming that
screening could reduce mortality and be cost-effective to
the same extent as expected without increasing harm,
high-risk subpopulations outside the USPSTF criteria
need to be reconsidereddespecially those who have
sustained smoking cessation beyond 15 years. By
considering the patients from the Olmsted County pop-
ulation, we were able to compare the local and referral
patients whose lung cancer was diagnosed during the
same time period (see Fig. 4).
We acknowledge several limitations. First, data from
Olmsted County may not be generalizable to the entire
United States in terms of racial distribution, disease
patterns, and access to care. White individuals, who are
known to have a lower incidence of lung cancer, are
overrepresented in Olmsted County. Second, although
we found that “quit smoking for 15 to 30 years” and
“smoked 20 to 30 pack-years” constitute the two
highest percentages of patient subgroups in both co-
horts, the proportions of patients in the hospital cohort
who were older than 81 years, were never smokers, had
a history of COPD, and had history of asbestos exposure
differed from those in the community cohortdlikely
because of referral practice and patients’ self-
preference. Third, we were unable to develop a pre-
diction model for individualized assessment of lung
cancer risk, as reported by other studies,26–31 because
doing so would require complete data on all known risk
factors in the entire Olmsted County population and
such data are not currently available. On the basis of the
modeling data provided by de Koning et al.,6 however,
we were able to indirectly project the impact of
extending the screened population to include former
smokers with more than 15 years of cessation, which
may signiﬁcantly increase the number of non-over-
diagnosed screen-detected lung cancers, save more
lives, and have an acceptable amount of increased scan
exposure and cost yet still be unlikely to signiﬁcantly
add false-positive cases.
Nonetheless, although our two prospective patient
cohorts differed signiﬁcantly in many aspects, they
provided consistent study results from a case detection
perspective (i.e., the relative proportions of patients with
known risk factors in whom lung cancer was diagnosed).
This is one of the efﬁcient designs for timely capture of
whether the end results of a disease under screeningreasonably reﬂects the predeﬁned high-risk population,
although obtaining the most deﬁnitive answer to justify a
change in high-risk deﬁnition being cost-effectiveness
requires calculating risks directly, having the denomi-
nator to know the number needed to screen, and
knowing how screening is implemented in the real
world.32
Conclusions
In both the community and hospital cohorts, the
trend in percentage of patients with lung cancer who
met the USPSTF criteria for inclusion in screening
decreased between 1997 and 2011. The trend toward
decreasing eligibility for screening in both cohorts
exceeded the decline in incidence over time, which
demonstrates that the current criteria for entry into lung
cancer screening did not identify those in whom lung
cancer actually developed. Inclusion of identiﬁable high-
risk subpopulations should be reconsidered to improve
current screening criteria. Our current and previous
studies provide evidence that former smokers with 15 to
30 quit-years remain at high risk and should be
considered eligible for LDCT screening for lung cancer.
The current USPSTF recommendation to stop screening
after 15 years of smoking cessation is not reﬂective of
the continued high risk, although participation of the
expanded population in the screening setting needs to be
further evaluated.
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